{"transactions":[{"id":1819776,"issuer":{"id":111009,"kind":"organization","name":"SPECTRUM PHARMACEUTICALS INC","symbol":"SPPI"},"owners":[{"id":83488,"kind":"person","name":"Brennan Nora","position":1,"cik":"0001790215","reported_name":"Brennan Nora","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-01T17:11:05.000Z","date":"2023-07-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1515957,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Stock options of the Issuer (the \"Company Options\") were canceled in the merger and (i) if the Company Option had an exercise price less than the Upfront Consideration, it was exchanged for (1) common stock of the Acquiror with a value equal to the quotient of (A) the product of (x) the total number of common stock of Issuer underlying the Company Option multiplied by (y) the excess, if any, of the value of the Upfront Consideration over the exercise price of such Company Option, divided by (B) the average of the daily volume-weighted average price per share of the common stock of Acquiror calculated based on the ten (10) consecutive trading days ending two trading days prior to the date of the Merger Agreement and (2) a number of CVRs equal to the number of shares of common stock of the Issuer underlying such Company Option, (ii) if the Company Option had an exercise price equal to or greater than the Upfront Consideration and less than the Merger Consideration,"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) it was exchanged for a number of CVRs equal to the number of common stock of the Issuer underlying such Company Option (reduced by the amount that the exercise price exceeds the Upfront Consideration) and (iii) if the Company Option had an exercise price equal to or greater than the Merger Consideration, it was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Stock options of the Issuer (the \"Company Options\") were canceled in the merger and (i) if the Company Option had an exercise price less than the Upfront Consideration, it was exchanged for (1) common stock of the Acquiror with a value equal to the quotient of (A) the product of (x) the total number of common stock of Issuer underlying the Company Option multiplied by (y) the excess, if any, of the value of the Upfront Consideration over the exercise price of such Company Option, divided by (B) the average of the daily volume-weighted average price per share of the common stock of Acquiror calculated based on the ten (10) consecutive trading days ending two trading days prior to the date of the Merger Agreement and (2) a number of CVRs equal to the number of shares of common stock of the Issuer underlying such Company Option, (ii) if the Company Option had an exercise price equal to or greater than the Upfront Consideration and less than the Merger Consideration,"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) it was exchanged for a number of CVRs equal to the number of common stock of the Issuer underlying such Company Option (reduced by the amount that the exercise price exceeds the Upfront Consideration) and (iii) if the Company Option had an exercise price equal to or greater than the Merger Consideration, it was canceled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Stock options of the Issuer (the \"Company Options\") were canceled in the merger and (i) if the Company Option had an exercise price less than the Upfront Consideration, it was exchanged for (1) common stock of the Acquiror with a value equal to the quotient of (A) the product of (x) the total number of common stock of Issuer underlying the Company Option multiplied by (y) the excess, if any, of the value of the Upfront Consideration over the exercise price of such Company Option, divided by (B) the average of the daily volume-weighted average price per share of the common stock of Acquiror calculated based on the ten (10) consecutive trading days ending two trading days prior to the date of the Merger Agreement and (2) a number of CVRs equal to the number of shares of common stock of the Issuer underlying such Company Option, (ii) if the Company Option had an exercise price equal to or greater than the Upfront Consideration and less than the Merger Consideration,"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"(Continued from Footnote 3) it was exchanged for a number of CVRs equal to the number of common stock of the Issuer underlying such Company Option (reduced by the amount that the exercise price exceeds the Upfront Consideration) and (iii) if the Company Option had an exercise price equal to or greater than the Merger Consideration, it was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":0.71,"underlying":"Common Stock","underlying_shares":1515957},"source":{"system":"sec-edgar","filing":"0000899243-23-017673","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/831547/000089924323017673/doc4.xml","form_type":"4"}},{"id":1819775,"issuer":{"id":111009,"kind":"organization","name":"SPECTRUM PHARMACEUTICALS INC","symbol":"SPPI"},"owners":[{"id":83488,"kind":"person","name":"Brennan Nora","position":1,"cik":"0001790215","reported_name":"Brennan Nora","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-08-01T17:11:05.000Z","date":"2023-07-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":840000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Stock options of the Issuer (the \"Company Options\") were canceled in the merger and (i) if the Company Option had an exercise price less than the Upfront Consideration, it was exchanged for (1) common stock of the Acquiror with a value equal to the quotient of (A) the product of (x) the total number of common stock of Issuer underlying the Company Option multiplied by (y) the excess, if any, of the value of the Upfront Consideration over the exercise price of such Company Option, divided by (B) the average of the daily volume-weighted average price per share of the common stock of Acquiror calculated based on the ten (10) consecutive trading days ending two trading days prior to the date of the Merger Agreement and (2) a number of CVRs equal to the number of shares of common stock of the Issuer underlying such Company Option, (ii) if the Company Option had an exercise price equal to or greater than the Upfront Consideration and less than the Merger Consideration,"},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"(Continued from Footnote 3) it was exchanged for a number of CVRs equal to the number of common stock of the Issuer underlying such Company Option (reduced by the amount that the exercise price exceeds the Upfront Consideration) and (iii) if the Company Option had an exercise price equal to or greater than the Merger Consideration, it was canceled for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Stock options of the Issuer (the \"Company Options\") were canceled in the merger and (i) if the Company Option had an exercise price less than the Upfront Consideration, it was exchanged for (1) common stock of the Acquiror with a value equal to the quotient of (A) the product of (x) the total number of common stock of Issuer underlying the Company Option multiplied by (y) the excess, if any, of the value of the Upfront Consideration over the exercise price of such Company Option, divided by (B) the average of the daily volume-weighted average price per share of the common stock of Acquiror calculated based on the ten (10) consecutive trading days ending two trading days prior to the date of the Merger Agreement and (2) a number of CVRs equal to the number of shares of common stock of the Issuer underlying such Company Option, (ii) if the Company Option had an exercise price equal to or greater than the Upfront Consideration and less than the Merger Consideration,"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"(Continued from Footnote 3) it was exchanged for a number of CVRs equal to the number of common stock of the Issuer underlying such Company Option (reduced by the amount that the exercise price exceeds the Upfront Consideration) and (iii) if the Company Option had an exercise price equal to or greater than the Merger Consideration, it was canceled for no consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Stock options of the Issuer (the \"Company Options\") were canceled in the merger and (i) if the Company Option had an exercise price less than the Upfront Consideration, it was exchanged for (1) common stock of the Acquiror with a value equal to the quotient of (A) the product of (x) the total number of common stock of Issuer underlying the Company Option multiplied by (y) the excess, if any, of the value of the Upfront Consideration over the exercise price of such Company Option, divided by (B) the average of the daily volume-weighted average price per share of the common stock of Acquiror calculated based on the ten (10) consecutive trading days ending two trading days prior to the date of the Merger Agreement and (2) a number of CVRs equal to the number of shares of common stock of the Issuer underlying such Company Option, (ii) if the Company Option had an exercise price equal to or greater than the Upfront Consideration and less than the Merger Consideration,"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"(Continued from Footnote 3) it was exchanged for a number of CVRs equal to the number of common stock of the Issuer underlying such Company Option (reduced by the amount that the exercise price exceeds the Upfront Consideration) and (iii) if the Company Option had an exercise price equal to or greater than the Merger Consideration, it was canceled for no consideration."}],"balance_after":0,"derivative":{"exercise_price":0.38,"underlying":"Common Stock","underlying_shares":840000},"source":{"system":"sec-edgar","filing":"0000899243-23-017673","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/831547/000089924323017673/doc4.xml","form_type":"4"}},{"id":1819774,"issuer":{"id":111009,"kind":"organization","name":"SPECTRUM PHARMACEUTICALS INC","symbol":"SPPI"},"owners":[{"id":83488,"kind":"person","name":"Brennan Nora","position":1,"cik":"0001790215","reported_name":"Brennan Nora","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock, $0.001 par value","published_at":"2023-08-01T17:11:05.000Z","date":"2023-07-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":463005,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Represents shares underlying restricted stock units of the Issuer, which were disposed of pursuant to the Merger Agreement in exchange for the aggregate Merger Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-017673","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/831547/000089924323017673/doc4.xml","form_type":"4"}},{"id":1819773,"issuer":{"id":111009,"kind":"organization","name":"SPECTRUM PHARMACEUTICALS INC","symbol":"SPPI"},"owners":[{"id":83488,"kind":"person","name":"Brennan Nora","position":1,"cik":"0001790215","reported_name":"Brennan Nora","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock, $0.001 par value","published_at":"2023-08-01T17:11:05.000Z","date":"2023-07-31","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":104823,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Represents shares of the Issuer disposed of pursuant to the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of April 24, 2023, by and among the Issuer, Assertio Holdings, Inc., a Delaware corporation (\"Acquiror\"), and Spade Merger Sub 1, Inc., a Delaware corporation and a wholly owned subsidiary of Acquiror, in exchange for consideration of (a) 0.1783 of a share of the common stock of Acquiror and cash in lieu of fractional shares (the \"Upfront Consideration\") and (b) a contingent value right (\"CVR\") to receive up to an additional $0.20 per common share (subject to adjustment), payable in cash or common stock of Acquiror at the election of Acquiror, upon the achievement of certain milestones, (the Upfront Consideration plus one CVR, collectively, the \"Merger Consideration\") on the effective date of the merger."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-017673","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/831547/000089924323017673/doc4.xml","form_type":"4"}},{"id":1875581,"issuer":{"id":111009,"kind":"organization","name":"SPECTRUM PHARMACEUTICALS INC","symbol":"SPPI"},"owners":[{"id":83488,"kind":"person","name":"Brennan Nora","position":1,"cik":"0001790215","reported_name":"Brennan Nora","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO"}}],"security":"Common Stock, $0.001 par value","published_at":"2023-05-30T19:36:11.000Z","date":"2023-05-26","kind":"sale","planned":false,"acquired":false,"shares":32387,"price":1.096,"value":35496.152,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for the purpose of satisfying tax withholding obligations in connection with restricted stock awards granted by the issuer."}],"balance_after":567828,"source":{"system":"sec-edgar","filing":"0000950170-23-025014","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/831547/000095017023025014/ownership.xml","form_type":"4"}},{"id":2064387,"issuer":{"id":111009,"kind":"organization","name":"SPECTRUM PHARMACEUTICALS INC","symbol":"SPPI"},"owners":[{"id":83488,"kind":"person","name":"Brennan Nora","position":1,"cik":"0001790215","reported_name":"Brennan Nora","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to Buy)","published_at":"2023-01-05T19:49:14.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":840000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One third of the aggregate amount of option shares shall vest on each of January 3, 2024, 2025 and 2026, respectively."}],"balance_after":840000,"derivative":{"exercise_price":0.38,"expiration_date":"2033-01-03","underlying":"Common Stock","underlying_shares":840000},"source":{"system":"sec-edgar","filing":"0000899243-23-001064","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/831547/000089924323001064/doc4.xml","form_type":"4"}},{"id":2064386,"issuer":{"id":111009,"kind":"organization","name":"SPECTRUM PHARMACEUTICALS INC","symbol":"SPPI"},"owners":[{"id":83488,"kind":"person","name":"Brennan Nora","position":1,"cik":"0001790215","reported_name":"Brennan Nora","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock, $0.001 par value","published_at":"2023-01-05T19:49:14.000Z","date":"2023-01-03","kind":"grant","acquired":true,"shares":240000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"One third of the aggregate amount of restricted stock units shall vest on each of January 3, 2024, 2025 and 2026, respectively."}],"balance_after":600215,"source":{"system":"sec-edgar","filing":"0000899243-23-001064","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/831547/000089924323001064/doc4.xml","form_type":"4"}},{"id":2223489,"issuer":{"id":111009,"kind":"organization","name":"SPECTRUM PHARMACEUTICALS INC","symbol":"SPPI"},"owners":[{"id":83488,"kind":"person","name":"Brennan Nora","position":1,"cik":"0001790215","reported_name":"Brennan Nora","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-23T19:56:35.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":1515957,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F3","text":"The option grant was approved by Spectrum's board of directors on May 25, 2022, subject to stockholder approval of the Plan under which the option was granted.  Spectrum's stockholders approved the Plan on June 21, 2022."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One third of the aggregate amount of option shares shall vest on each of May 25, 2023, 2024 and 2025, respectively."}],"balance_after":1515957,"derivative":{"exercise_price":0.71,"expiration_date":"2032-05-25","underlying":"Common Stock","underlying_shares":1515957},"source":{"system":"sec-edgar","filing":"0001209191-22-039057","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/831547/000120919122039057/doc4.xml","form_type":"4"}},{"id":2223488,"issuer":{"id":111009,"kind":"organization","name":"SPECTRUM PHARMACEUTICALS INC","symbol":"SPPI"},"owners":[{"id":83488,"kind":"person","name":"Brennan Nora","position":1,"cik":"0001790215","reported_name":"Brennan Nora","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Common Stock, $0.001 par value","published_at":"2022-06-23T19:56:35.000Z","date":"2022-06-21","kind":"sale","acquired":false,"shares":3569,"price":0.785,"value":2801.665,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"All sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person for the purpose of satisfying tax withholding obligations in connection with restricted stock awards granted by the issuer."}],"balance_after":360215,"source":{"system":"sec-edgar","filing":"0001209191-22-039057","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/831547/000120919122039057/doc4.xml","form_type":"4"}},{"id":2223487,"issuer":{"id":111009,"kind":"organization","name":"SPECTRUM PHARMACEUTICALS INC","symbol":"SPPI"},"owners":[{"id":83488,"kind":"person","name":"Brennan Nora","position":1,"cik":"0001790215","reported_name":"Brennan Nora","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"EVP & CFO"}}],"security":"Common Stock, $0.001 par value","published_at":"2022-06-23T19:56:35.000Z","date":"2022-06-21","kind":"grant","acquired":true,"shares":334507,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The restricted stock unit grant was approved by Spectrum Pharmaceuticals, Inc's (\"Spectrum\") board of directors on May 25, 2022, subject to stockholder approval of the Amended and Restated 2018 Long-Term Incentive Plan (the \"Plan\") under which the restricted stock unit was granted.  Spectrum's stockholders approved the Plan on June 21, 2022."}],"balance_after":363784,"source":{"system":"sec-edgar","filing":"0001209191-22-039057","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/831547/000120919122039057/doc4.xml","form_type":"4"}},{"id":2659667,"issuer":{"id":111009,"kind":"organization","name":"SPECTRUM PHARMACEUTICALS INC","symbol":"SPPI"},"owners":[{"id":83488,"kind":"person","name":"Brennan Nora","position":1,"cik":"0001790215","reported_name":"Brennan Nora","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-06-22T18:35:45.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":67804,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One third of the aggregate amount of option shares shall vest on each of June 17, 2022, 2023 and 2024, respectively."}],"balance_after":67804,"derivative":{"exercise_price":4.29,"expiration_date":"2031-06-17","underlying":"Common Stock","underlying_shares":67804},"source":{"system":"sec-edgar","filing":"0001209191-21-042511","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/831547/000120919121042511/doc4.xml","form_type":"4"}},{"id":2659666,"issuer":{"id":111009,"kind":"organization","name":"SPECTRUM PHARMACEUTICALS INC","symbol":"SPPI"},"owners":[{"id":83488,"kind":"person","name":"Brennan Nora","position":1,"cik":"0001790215","reported_name":"Brennan Nora","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2021-06-22T18:35:45.000Z","date":"2021-06-17","kind":"grant","acquired":true,"shares":14277,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"100% of the restricted shares shall vest on the earlier of (1) June 17, 2022 or (2) the date of the company's 2022 Annual Meeting of Stockholders."}],"balance_after":29277,"source":{"system":"sec-edgar","filing":"0001209191-21-042511","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/831547/000120919121042511/doc4.xml","form_type":"4"}},{"id":2760448,"issuer":{"id":7381,"kind":"organization","name":"TELA Bio, Inc.","symbol":"TELA"},"owners":[{"id":83488,"kind":"person","name":"Brennan Nora","position":1,"cik":"0001790215","reported_name":"Brennan Nora","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-04-02T18:41:14.000Z","date":"2021-03-31","kind":"grant","acquired":true,"shares":2928,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units will vest in four equal annual installments beginning on March 31, 2022, subject to the Reporting Person's continuous service with the Issuer."}],"balance_after":17696,"source":{"system":"sec-edgar","filing":"0001192482-21-000297","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1561921/000119248221000297/edgar.xml","form_type":"4"}},{"id":2829031,"issuer":{"id":7381,"kind":"organization","name":"TELA Bio, Inc.","symbol":"TELA"},"owners":[{"id":83488,"kind":"person","name":"Brennan Nora","position":1,"cik":"0001790215","reported_name":"Brennan Nora","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-26T22:25:32.000Z","date":"2021-02-24","kind":"grant","acquired":true,"shares":20100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests 25% on February 24, 2022, with the remaining 75% vesting in equal monthly installments on the last day of each of the 36 calendar months immediately following such date, subject to the Reporting Person's continuous service with the Issuer."}],"balance_after":20100,"derivative":{"exercise_price":16.99,"expiration_date":"2031-02-24","underlying":"Common Stock","underlying_shares":20100},"source":{"system":"sec-edgar","filing":"0001192482-21-000189","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1561921/000119248221000189/edgar.xml","form_type":"4"}},{"id":2829030,"issuer":{"id":7381,"kind":"organization","name":"TELA Bio, Inc.","symbol":"TELA"},"owners":[{"id":83488,"kind":"person","name":"Brennan Nora","position":1,"cik":"0001790215","reported_name":"Brennan Nora","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2021-02-26T22:25:32.000Z","date":"2021-02-24","kind":"grant","acquired":true,"shares":11100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"These restricted stock units will vest in four equal annual installments beginning on February 24, 2022, subject to the Reporting Person's continuous service with the Issuer."}],"balance_after":14768,"source":{"system":"sec-edgar","filing":"0001192482-21-000189","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1561921/000119248221000189/edgar.xml","form_type":"4"}},{"id":2947517,"issuer":{"id":111009,"kind":"organization","name":"SPECTRUM PHARMACEUTICALS INC","symbol":"SPPI"},"owners":[{"id":83488,"kind":"person","name":"Brennan Nora","position":1,"cik":"0001790215","reported_name":"Brennan Nora","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-12-14T16:05:50.000Z","date":"2020-12-10","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One third of the aggregate amount of option shares shall vest on each of December 10, 2021, 2022 and 2023, respectively."}],"balance_after":30000,"derivative":{"exercise_price":4.69,"expiration_date":"2030-12-10","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001209191-20-063198","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/831547/000120919120063198/doc4.xml","form_type":"4"}},{"id":2947516,"issuer":{"id":111009,"kind":"organization","name":"SPECTRUM PHARMACEUTICALS INC","symbol":"SPPI"},"owners":[{"id":83488,"kind":"person","name":"Brennan Nora","position":1,"cik":"0001790215","reported_name":"Brennan Nora","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock, $0.001 par value","published_at":"2020-12-14T16:05:50.000Z","date":"2020-12-10","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"100% of the restricted shares shall vest on June 17, 2021."}],"balance_after":15000,"source":{"system":"sec-edgar","filing":"0001209191-20-063198","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/831547/000120919120063198/doc4.xml","form_type":"4"}},{"id":3372547,"issuer":{"id":7381,"kind":"organization","name":"TELA Bio, Inc.","symbol":"TELA"},"owners":[{"id":83488,"kind":"person","name":"Brennan Nora","position":1,"cik":"0001790215","reported_name":"Brennan Nora","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Series B Preferred Stock","published_at":"2019-11-14T01:52:51.000Z","date":"2019-11-13","kind":"exercise","acquired":false,"shares":86200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3491},"source":{"system":"sec-edgar","filing":"0001192482-19-000425","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1561921/000119248219000425/edgar.xml","form_type":"4"}},{"id":3372546,"issuer":{"id":7381,"kind":"organization","name":"TELA Bio, Inc.","symbol":"TELA"},"owners":[{"id":83488,"kind":"person","name":"Brennan Nora","position":1,"cik":"0001790215","reported_name":"Brennan Nora","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2019-11-14T01:52:51.000Z","date":"2019-11-13","kind":"exercise","acquired":true,"shares":3491,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares of Series B Preferred Stock automatically converted into shares of Common Stock at a 1-for-1 conversion rate upon the closing of the Issuer's initial public offering and had no expiration date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects 1-for-24.69 reverse stock split which became effective on October 28, 2019."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Reflects 177 shares of common stock received by the reporting person as a payment-in-kind dividend on Series B Preferred Stock exempt from reporting under Rule 16a-9(a)."}],"balance_after":3668,"source":{"system":"sec-edgar","filing":"0001192482-19-000425","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1561921/000119248219000425/edgar.xml","form_type":"4"}}]}